Bvf Inc X4 Pharmaceuticals, Inc Transaction History

Bvf Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $344,841 - $1.1 Million	499,771 Added 58.94%	1,347,650 $1.33 Million
Q2 2021 Aug 16, 2021	SELL	$6.49 - $9.56 $1.58 Million - $2.33 Million	-243,700 Reduced 22.33%	847,879 $5.51 Million
Q1 2021 May 17, 2021	BUY	$6.63 - $10.28 $1.98 Million - $3.07 Million	298,687 Added 37.67%	1,091,579 $9.4 Million
Q3 2020 Nov 13, 2020	SELL	$6.09 - $9.15 $1.33 Million - $1.99 Million	-218,000 Reduced 21.57%	792,892 $5.37 Million
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $1.28 Million - $1.68 Million	-160,836 Reduced 13.73%	1,010,892 $9.42 Million
Q1 2020 May 15, 2020	BUY	$6.03 - $11.01 $179,416 - $327,591	29,754 Added 2.61%	1,171,728 $11.7 Million
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $5.45 Million - $7.86 Million	548,500 Added 92.42%	1,141,974 $12.2 Million
Q3 2019 Nov 14, 2019	BUY	$11.06 - $15.75 $143,492 - $204,340	12,974 Added 2.23%	593,474 $7.54 Million
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $7.3 Million - $12.6 Million	580,500 New	580,500 $8.71 Million

105

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.